Skip to content

Study · Not a test of the peptide alone · 2025

2 results

Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases.

Ren H, Yu X, Li M, Luo Z, Lin Y, Meng Y, Cheng Q, Wei T

Nano letters8 Sept 2025Cited by 2 (Europe PMC)

PMID40916925 (opens in a new tab)DOI10.1021/acs.nanolett.5c03184 (opens in a new tab)PepBankPUB-40916925
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In a type 2 diabetes model, nebulized liver-targeted nanoparticles delivered dulaglutide mRNA that expressed in the liver.

    In plain wordsIn a diabetes model, nanoparticles carrying dulaglutide genetic instructions produced liver expression.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHepatic expression
    Study

    n: not reported in source

    Type 2 diabetes model
    Outcome group
    Receptor activity and mechanism · Liver

    Source sentences

    Summary
    In a Type 2 diabetes model, dulaglutide mRNA was effectively expressed in the liver and exhibited good hypoglycemic effects.
    1 context sentence
    Summary · context
    Using nebulized liver-targeted LNPs (NebuLi LNPs), we successfully delivered therapeutic mRNAs for the treatment of metabolic diseases.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In a type 2 diabetes model, liver-targeted delivery of dulaglutide mRNA produced hypoglycemic effects.

    In plain wordsIn a diabetes model, liver-targeted dulaglutide genetic instructions lowered blood sugar.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHypoglycemic effects
    Study

    n: not reported in source

    Type 2 diabetes model
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In a Type 2 diabetes model, dulaglutide mRNA was effectively expressed in the liver and exhibited good hypoglycemic effects.
    1 context sentence
    Summary · context
    Using nebulized liver-targeted LNPs (NebuLi LNPs), we successfully delivered therapeutic mRNAs for the treatment of metabolic diseases.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.